The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

29 Apr 2010 09:02

RNS Number : 0230L
e-Therapeutics plc
29 April 2010
 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Issue of Equity and Director's award of Options

 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

 

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

 

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

 

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

 

Name

Ordinary Shares owned

Options over Ordinary Shares

Number

Number

Exercise Price

Date at which exercisable

Oliver James

38,500

118,020

£0.67

Vested

25,000

£0.385

28 April 2013

Brad Hoy

80,000

£0.375

Vested

25,000

£0.385

28 April 2013

 

 

 

- Ends -

 

 

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

malcolm@etherapeutics.co.uk

+44 (0) 191 233 1317

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

henry.fitzgerald-o'connor@canaccordadams.com

+44 (0) 20 7050 6500

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

simone.elviss@abchurch-group.com

+44 (0) 20 7398 7700

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFSAUFSSESL
Date   Source Headline
9th May 20247:00 amRNSCancellation - e-Therapeutics Plc
8th May 20247:00 amRNSLast Day of Dealings on AIM
3rd May 20246:00 pmRNSe-therapeutics
29th Apr 20242:09 pmRNSResult of General Meeting
10th Apr 20247:00 amRNSProposed Fundraise of £28.9m and Cancellation
31st Jan 20244:30 pmRNSTotal Voting Rights
24th Jan 202410:04 amRNSExercise of Options and Issue of Equity
16th Jan 20247:00 amRNSBusiness Update
9th Jan 20244:04 pmRNSDirector Dealing and Issue of Equity
27th Dec 20237:00 amRNSUpdate on OTCQX Market Listing
13th Nov 20239:05 amEQSEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
2nd Nov 20237:00 amRNSStrategic RWE collaboration with Arcturis
26th Oct 20237:38 amRNSInterim results for the six months to 31 July 2023
19th Oct 20239:54 amRNSNotice of Interim Results
20th Sep 20237:00 amRNSSenior Management Update
7th Sep 202311:47 amRNSExercise of Options and Issue of Equity
31st Jul 20234:30 pmRNSTotal Voting Rights
18th Jul 20234:20 pmRNSResult of Annual General Meeting
6th Jul 20235:27 pmRNSDirector Dealing and Issue of Equity
30th Jun 20237:00 amRNSInvestor Presentation
26th Jun 20237:00 amRNSNotice of Investor Presentation
11th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20237:00 amRNSFinal results for the year ended 31 January 2023
28th Apr 20234:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSNotification of Full Year Results Date
28th Mar 20233:57 pmRNSExercise of Options and Issue of Equity
21st Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 202310:19 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSFiling of four patent applications
31st Jan 20237:00 amRNSTotal Voting Rights
4th Jan 20233:15 pmRNSDirector Dealing and Issue of Equity
29th Dec 20224:40 pmRNSSecond Price Monitoring Extn
29th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20224:35 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSTotal Voting Rights
12th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 202210:42 amRNSHolding(s) in Company
10th Oct 20228:03 amRNSHolding(s) in Company
30th Sep 20227:00 amRNSInterim results for the six months to 31 July 2022
30th Sep 20227:00 amRNSFundraise of £13.5 million by way of Subscription
26th Sep 20224:40 pmRNSSecond Price Monitoring Extn
26th Sep 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20227:00 amRNSFiling of eight patent applications
29th Jul 20227:00 amRNSTotal Voting Rights
20th Jul 202210:39 amRNSResult of Annual General Meeting
6th Jul 20227:00 amRNSNotice to Shareholders - AGM Virtual Access
5th Jul 20227:00 amRNSDirector Dealing and Issue of Equity
17th May 20227:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20227:00 amRNSFinal results for the year ended 31 January 2022
27th Apr 20227:00 amRNSNotification of Full Year Results Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.